secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093339
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q2 net loss widens to $147M; NTLA-2002 Phase 2 meets endpoints, Phase 3 on track
--------------------------------------------------------------------------------

- NTLA-2002 Phase 2 for HAE met primary and all secondary endpoints; 50 mg dose selected for pivotal Phase 3, on track to start 2H 2024.
- Phase 3 MAGNITUDE trial (NTLA-2001 for ATTR-CM) enrolling rapidly across >12 countries and >35 sites.
- Plans to initiate Phase 3 of NTLA-2001 for ATTRv-PN by year-end and dose first patient in NTLA-3001 Phase 1/2 for AATD in 2H 2024.
- Q2 2024 net loss $147.0M vs $123.7M YoY; cash $939.9M expected to fund operations into late 2026.
- Appointed Edward Dulac as CFO effective July 22 and Brian Goff to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024093339/0000950170-24-093339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024093339/ntla-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer